RIGEL PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Amortized Cost
RIGEL PHARMACEUTICALS, INC. (RIGL) had Debt Securities, Available-for-sale, Amortized Cost of $108.95 million as of 2025-09-30, per its 10-Q filed 2025-11-04.
Financial Statements › Notes › Credit Loss, Additional Improvements
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2025-11-04
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $108.95M.
- 2025-06-30: Debt Securities, Available-for-sale, Amortized Cost $73.59M.
- 2025-03-31: Debt Securities, Available-for-sale, Amortized Cost $46.32M.
- 2024-12-31: Debt Securities, Available-for-sale, Amortized Cost $40.79M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2025-09-30 | $108.95M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $73.59M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $46.32M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $40.79M 10-Q · filed 2025-11-04 |
| 2024-09-30 | $23.18M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $29.18M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $33.95M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $38.99M 10-K · filed 2025-03-04 |
| 2023-09-30 | $38.07M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $34.48M 10-Q · filed 2023-08-01 |
| 2023-03-31 | $38.40M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $47.94M 10-K · filed 2024-03-05 |
| 2022-09-30 | $70.14M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $67.90M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $91.50M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $111.98M 10-K · filed 2023-03-07 |
| 2021-09-30 | $114.73M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $94.55M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $26.40M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $35.86M 10-K · filed 2022-03-01 |
| 2020-09-30 | $53.69M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $67.98M 10-Q · filed 2020-08-04 |
| 2020-03-31 | $57.32M 10-Q · filed 2020-05-05 |
| 2019-12-31 | $87.23M 10-K · filed 2021-03-02 |
| 2019-09-30 | $78.89M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $100.18M 10-Q · filed 2019-08-06 |
| 2018-12-31 | $116.83M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |